CN101406657B - Chinese medicine compound for treating lung cancer and manufacturing method thereof - Google Patents
Chinese medicine compound for treating lung cancer and manufacturing method thereof Download PDFInfo
- Publication number
- CN101406657B CN101406657B CN200810159997XA CN200810159997A CN101406657B CN 101406657 B CN101406657 B CN 101406657B CN 200810159997X A CN200810159997X A CN 200810159997XA CN 200810159997 A CN200810159997 A CN 200810159997A CN 101406657 B CN101406657 B CN 101406657B
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- chinese medicine
- medicine composition
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicine composition for treating lung cancer. The Chinese medicine composition comprises the following active pharmaceutical ingredients in portion by weight: 10 to 15 potions of dandelion, 4 to 10 potions of licorice, 20 to 25 potions of ginseng, 20 to 25 potions of giant knotweed, 3 to 10 portions of rhizoma zedoariae, 10 tp 15 portions of Houttuynia cordata Thunb, 15 to 18 portions of Draconis Resina, 5 to 7 portions of indigo, 3 to 5 portions of asarum, 5 to 15 portions of sealwort and 6 to 15 portions of medlar. The Chinese medicine composition is prepared as follows: extracting ginseng with 90 to 95 percent ethanol in a reflux mode; grinding Draconis Resina and asarum and screening Draconis Resina and asarum powder; boiling twice the other active pharmaceutical ingredients added with water; combining decoctions and filtering the mixed decoctions; adding an extract of ginseng and powder of Draconis Resina and asarum into a filtrate in turn with even mixing; condensing the mixture to form a paste; and making the past into various pharmaceutical preparation forms. The Chinese medicine composition achieves remarkable curative effect, improvement on immunity of human bodies and mild function, produces no toxic side effects and is simple in preparation process and low in price.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of pulmonary carcinoma and preparation method thereof, belong to the medical sci-tech technical field.
Background technology
Pulmonary carcinoma is modal lung primary malignant tumor, and its M ﹠ M is ascendant trend year by year.The prognosis of pulmonary carcinoma early operation therapeutic effect is preferable, but because symptom is not obvious, has been middle and advanced stage when most of patients is made a definite diagnosis, and has lost the chance of operative treatment, generally can only take the treatment means of radiation and chemotherapy.Chemotherapeutics commonly used at present is cisplatin, carboplatin, mitomycin, 5-fluorouracil, bleomycin etc., though tumor cell is had certain inhibitory action, but toxic and side effects is very big, and the normal cell and the organ of human body had great harm, has had a strong impact on the quality of life of tumor patient.In recent years, Chinese medicine more and more was subjected to people's attention in the application of anticancer aspect, as cantharidin, wall-breaking lucidum etc., but single when using its active constituent content lower, onset is slow, and action effect is also not satisfactory.
Summary of the invention
The objective of the invention is to overcome the deficiency of existing Chinese medicine preparation, provide that a kind of therapeutic effect is good, toxic and side effects is little, the Chinese medicine composition of the treatment pulmonary carcinoma of instant effect.
Another object of the present invention provides the preparation method of above-mentioned Chinese medicine composition.
The present invention is achieved by the following measures:
The Chinese medicine composition of treatment pulmonary carcinoma of the present invention, make by following raw medicaments in portion by weight:
3～10 parts of 20～25 parts of Rhizoma Curcumae of 20～25 parts of Rhizoma Polygoni Cuspidati of 4～10 parts of Radix Ginsengs of 10～15 portions of Radix Glycyrrhizaes of Herba Taraxaci
5～15 parts of 3～5 parts of Rhizoma Polygonatis of 5～7 parts of Herba Asaris of 15～18 parts of Indigo Naturaliss of 10～15 parts of Sanguis Draxonis of Herba Houttuyniae
6～15 parts of Fructus Lyciis.
The Chinese medicine composition of above-mentioned treatment pulmonary carcinoma, it is preferably filled a prescription and is: made by following raw medicaments in portion by weight:
12 parts of 7 parts of Herba Houttuyniae of 22 parts of Rhizoma Curcumae of 22 parts of Rhizoma Polygoni Cuspidati of 7 parts of Radix Ginsengs of 12 portions of Radix Glycyrrhizaes of Herba Taraxaci
10 parts of 10 portions of Fructus Lyciis of 4 parts of Rhizoma Polygonatis of 6 parts of Herba Asaris of 16 parts of Indigo Naturaliss of Sanguis Draxonis.
The preparation method of the Chinese medicine composition of above-mentioned treatment pulmonary carcinoma, adopt following steps:
(1) Radix Ginseng adds 90%～95% ethanol, and reflux, extract, is after extracting solution reclaims ethanol, standby;
(2) Sanguis Draxonis, Herba Asari are pulverized sieving for standby;
(3) all the other medicines decoct with water 2 times, each 1～2 hour, merge the medicinal liquid that decocts for 2 times, filter, being concentrated into relative density is 1.05～1.08, adds the powder of above-mentioned Radix Ginseng extractive solution and Sanguis Draxonis, Herba Asari successively, stir, be concentrated into paste, make the various dosage forms on the pharmaceutics.
Various dosage forms on the described pharmaceutics can be any in tablet, pill, capsule, powder, oral liquid, the electuary.
The traditional Chinese medical science thinks that pulmonary carcinoma is because healthy energy is deficient, the long-term coefficient result of evil poison invasion and attack.Therefore when treatment, note supplementing QI and nourishing YIN, all very important to expectorant, poison, silt, invigorating spleen and reinforcing stomach is also very important.The spleen and stomach provide the material basis of the acquired, source of generating QI and blood.Invigorating spleen and reinforcing stomach can strengthen the human righteousness, human body immunity improving power, and this all has effect preferably for improving patients ' life quality and prolonging life cycle.
Select for use the effect of the crude drug of respectively distinguishing the flavor of as follows in the prescription of the present invention:
The Radix Glycyrrhizae relieving cough and resolving phlegm, tonifying the spleen and stomach has synergism to detoxifcation.
Radix Ginseng has the effect of invigorating primordial QI, invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, the Fructus Alpiniae Oxyphyllae of calming the nerves.Modern study shows that Radix Ginseng has the enhancing hematopoietic function, promotes proliferation of bone marrow cells, human body immunity improving power and antineoplastic action.
Rhizoma Polygoni Cuspidati has the effect of blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, dampness removing jaundice eliminating, preventing phlegm from forming and stopping coughing.Modern study shows that it has leukocyte increasing, presses down cancer, analgesia and antiphlogistic effect.
Herba Taraxaci has the effect of heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, inducing diuresis for treating stranguria syndrome, and energy excitating organism immunologic function has protective effect to hepatic injury.
Herba Houttuyniae has the effect of heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, inducing diuresis for treating stranguria syndrome.Modern study shows that it can enhancing human body immunity power and antineoplastic action.
Sanguis Draxonis is flat, and sweet in the mouth, salty has blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, hemostasia and promoting granulation function.
The Indigo Naturalis heat-clearing and toxic substances removing, removing heat from blood, arresting convulsion.Be used for maculae caused by violent heat pathogen, heat in blood is told nosebleed, the chest pain hemoptysis, and aphtha, mumps, sore throat, pediatric epilepsy scared has the effect of enhancing human body immunity power and inhibition tumor.
Rhizoma Curcumae acrid in the mouth, hardship, warm in nature.Effect with removing blood stasis, promoting the circulation of QI to relieve pain, modern study show, have antitumor, antiearly pregnancy, antibacterial, promote leukocyte increasing, protect the liver, effects such as antiinflammatory, anticoagulant.
Herba Asari has expelling wind and cold, understand things pain-stopping, the effect of warming the lung to resolve fluid-retention.
The Fructus Lycii the kidney invigorating and essence nourishing, nourishing the liver to improve visual acuity, blood-enriching tranquillizing, promoting the production of body fluid to quench thirst, nourishing the lung to arrest cough.Join Rhizoma Polygonati, but nourishing YIN and supplementing blood, Fructus Lycii helps the Rhizoma Polygonati nourishing YIN and moistening the lung, and Rhizoma Polygonati helps Fructus Lycii to nourish cloudy blood, and mutual reinforcement between is for using.
Rhizoma Polygonati has boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney benefiting functions.Be used for the treatment of weakness of the spleen and stomach, fatigue and asthenia, xerostomia lack of appetite, deficiency of the lung cough caused by dryness, asthenia of essence and blood, interior-heat disease such as quench one's thirst.
The invention has the beneficial effects as follows: Chinese medicine composition of the present invention has the effect of blood circulation promoting and blood stasis dispelling, nourishing the lung to arrest cough, function of spleen and stomach regulating, and energy enhancing human body immunity power, and is evident in efficacy, action temperature and, no obvious toxic and side effects, preparation technology is simple, cheap, the patient is easy to accept.
The specific embodiment
Embodiment 1
The Chinese medicine composition of treatment pulmonary carcinoma of the present invention, filling a prescription is:
Herba Taraxaci 1200g Radix Glycyrrhizae 700g Radix Ginseng 2200g Rhizoma Polygoni Cuspidati 2200g Rhizoma Curcumae 700g
Herba Houttuyniae 1200g Sanguis Draxonis 1600g Indigo Naturalis 600g Herba Asari 400g Rhizoma Polygonati 1000g Fructus Lycii 1000g.
Preparation method:
(1) Radix Ginseng is added 90% ethanol, reflux, extract,, after extracting solution reclaims ethanol, standby;
(2) Sanguis Draxonis, Herba Asari are pulverized, it is standby to cross 100 mesh sieves;
(3) all the other medicines decoct with water 2 times, and each 1.5 hours, merge the medicinal liquid that decocts for 2 times, filter, being concentrated into relative density is 1.05, adds the powder of above-mentioned Radix Ginseng extractive solution and Sanguis Draxonis, Herba Asari successively, stirs, be concentrated into paste, granule is made in oven dry, incapsulates.
Every contains the about 0.24g of crude drug, is grown up each 3～4, every day 3 times or follow the doctor's advice.
Embodiment 2
The Chinese medicine composition of treatment pulmonary carcinoma of the present invention, filling a prescription is:
Herba Taraxaci 1000g Radix Glycyrrhizae 400g Radix Ginseng 2000g Rhizoma Polygoni Cuspidati 2000g Rhizoma Curcumae 300g
Herba Houttuyniae 1000g Sanguis Draxonis 1500g Indigo Naturalis 500g Herba Asari 300g Rhizoma Polygonati 500g Fructus Lycii 600g.
Preparation method:
(1) Radix Ginseng is added 95% ethanol, reflux, extract,, after extracting solution reclaims ethanol, standby;
(2) Sanguis Draxonis, Herba Asari are pulverized, it is standby to cross 100 mesh sieves;
(3) all the other medicines decoct with water 2 times, each 1 hour, merge the medicinal liquid that decocts for 2 times, filter, being concentrated into relative density is 1.06, adds the powder of above-mentioned Radix Ginseng extractive solution and Sanguis Draxonis, Herba Asari successively, stir, be concentrated into paste, make tablet according to a conventional method.
Every contains the about 0.2g of crude drug, 4～5 of the each clothes of adult, every day 3 times or follow the doctor's advice.
Embodiment 3
The Chinese medicine composition of treatment pulmonary carcinoma of the present invention, filling a prescription is:
Herba Taraxaci 1500g Radix Glycyrrhizae 1000g Radix Ginseng 2500g Rhizoma Polygoni Cuspidati 2500g Rhizoma Curcumae 1000g
Herba Houttuyniae 1500g Sanguis Draxonis 1800g Indigo Naturalis 700g Herba Asari 500g Rhizoma Polygonati 1500g Fructus Lycii 1500g.
Preparation method:
(1) Radix Ginseng is added 95% ethanol, reflux, extract,, after extracting solution reclaims ethanol, standby;
(2) Sanguis Draxonis, Herba Asari are pulverized, it is standby to cross 100 mesh sieves;
(3) all the other medicines decoct with water 2 times, each 2 hours, merge the medicinal liquid that decocts for 2 times, filter, being concentrated into relative density is 1.08, adds the powder of above-mentioned Radix Ginseng extractive solution and Sanguis Draxonis, Herba Asari successively, stir, be concentrated into paste, make oral liquid according to a conventional method.
Every milliliter contains the about 0.22g of crude drug, the each clothes of adult 5ml, every day 3 times or follow the doctor's advice.
Test case 1
The long term toxicity test of Chinese medicine composition of the present invention
Choose the SD rat, body weight is 180 ± 20g, male and female half and half, every day, the oral administration amount was 2g/kg, continuous use 6 months, the result shows: compare with matched group, the action of rat, hair, body weight, routine blood test, hepatic and renal function and organ coefficient all do not have marked difference, histological examination showed, and different nothings such as the heart, liver, spleen, lung, kidney obviously change, illustrate that long term toxicity is lower, takes safety.
Test case 2
The pharmacodynamic experiment of Chinese medicine composition of the present invention
1 cell strain: human lung carcinoma cell line A549.
2 animals: BALB/c-nu/nu nude mice.
3 medicines: experimental group: medicine of the present invention, gastric infusion.
Positive controls: 5-FU, intramuscular administration.
Negative control: normal saline.
4 kinds of foundation and administrations of planting the tumor model: above-mentioned cell culture to 90% is merged, centrifugal collecting cell, be made into single cell suspension, be injected to subcutaneous tissue under the BALB/c-nu/nu nude mice right side or the left rib, be divided into 3 groups of administrations at random, 2 weeks of successive administration, 24 hours execution nude mices after the last administration, peel off tumor and weigh, calculate tumour inhibiting rate, the results are shown in Table 1.
Table 1 different pharmaceutical is to the influence of plantation tumor
| Group | Dosage (g/kg) | Number of animals | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | ---- | 12 | 1.02±0.16 | 0 |
| Medicine group of the present invention | 0.5 | 12 | 0.56±0.08 | 45.1％ |
| Positive controls | 0.2 | 12 | 0.42±0.13 | 58.8％ |
| Medicine+positive controls of the present invention | 0.3?0.1? | 12? | 0.35±0.09? | 65.7％? |
As seen from the above table, a little less than positive controls, but both synergistic action effects are better than using separately positive control to medicine of the present invention, and have reduced the toxic and side effects of positive control to the inhibitory action of plantation tumor.
Test case 3
The clinical experiment data of medicine of the present invention
1 clinical data
Inpatient department picked at random 90 routine medium and advanced lung cancer patients, wherein male 56 examples, women 34 examples, the age is 44～75 years old, 54 years old mean age.All cases wherein are nonsmall-cell lung cancer through clinical, iconography and pathological diagnosis, and clinical III, IV phase, and all through the treatment of several different methods such as chemotherapy, radiotherapy, not good enough or toxic and side effects is accepted the treatment of medicine of the present invention too greatly because of effect.
2 Therapeutic Method
All cases are all taken the capsule of embodiment 1, and each 4, every day 3 times, 30 is a course of treatment.
3 clinical efficacy criterion
With reference to new drug clinical guidance principle, criterion is alleviated (CR): the cancer complete obiteration fully; Part is alleviated (PR): carcinoma reduces more than 50%; Stable effectively (MR): carcinoma reduces or increases all less than 25%; Make progress invalid (PD): carcinoma increases and greater than 25% or new focus occurs.
4 evaluation of result
After 3 courses of treatment, PR39 example, MR25 example, PD5 example.Total effective rate is 71%.
Take medicine of the present invention and do not see obvious adverse reaction.
5 model cases
In certain, the woman, 48 years old, the paroxysmal cough was surplus February, and sputum mixed with blood often feels uncomfortable in chest out of breath, is off one's feed weight loss.Through film making of X line and CT examination, be diagnosed as bottom right pulmonary carcinoma, the bottom right lung has 30 * 40mm shade.Because of chemotherapy side effect is too big, then accept Drug therapy of the present invention, take 4 months continuously after, film making is checked.Shade is contracted to 20 * 20mm, and symptom is obviously improved, and immunity strengthens.Continue to take medicine of the present invention at present.
Zhang, man, 56 years old, cough hemoptysis, chest pain, low grade fever, film making of X line and CT examination are diagnosed as lower-left pulmonary carcinoma, and there is 25 * 20mm shade in pulmonary, takes medicine of the present invention continuously after 2 months, subjective symptoms is clearly better, and the CT examination tumor is dwindled more than 50%, and after continuing to take 3 months, tumor cloud disappears.Recurrence is not seen in check in 2 months after the drug withdrawal.
Claims (3)
1. Chinese medicine composition for the treatment of pulmonary carcinoma is characterized in that: made by following raw medicaments in portion by weight:
3～10 parts of 20～25 parts of Rhizoma Curcumae of 20～25 parts of Rhizoma Polygoni Cuspidati of 4～10 parts of Radix Ginsengs of 10～15 portions of Radix Glycyrrhizaes of Herba Taraxaci
5～15 parts of 3～5 parts of Rhizoma Polygonatis of 5～7 parts of Herba Asaris of 15～18 parts of Indigo Naturaliss of 10～15 parts of Sanguis Draxonis of Herba Houttuyniae
6～15 parts of Fructus Lyciis.
2. the Chinese medicine composition of treatment pulmonary carcinoma according to claim 1 is characterized in that: made by following raw medicaments in portion by weight:
12 parts of 7 parts of Herba Houttuyniae of 22 parts of Rhizoma Curcumae of 22 parts of Rhizoma Polygoni Cuspidati of 7 parts of Radix Ginsengs of 12 portions of Radix Glycyrrhizaes of Herba Taraxaci
10 parts of 10 portions of Fructus Lyciis of 4 parts of Rhizoma Polygonatis of 6 parts of Herba Asaris of 16 parts of Indigo Naturaliss of Sanguis Draxonis.
3. the preparation method of the Chinese medicine composition of the described treatment pulmonary carcinoma of claim 1 is characterized in that adopting following steps:
(1) Radix Ginseng adds 90%～95% ethanol, and reflux, extract, is after extracting solution reclaims ethanol, standby;
(2) Sanguis Draxonis, Herba Asari are pulverized sieving for standby;
(3) all the other medicines decoct with water 2 times, each 1～2 hour, merge the medicinal liquid that decocts for 2 times, filter, being concentrated into relative density is 1.05～1.08, adds the powder of above-mentioned Radix Ginseng extractive solution and Sanguis Draxonis, Herba Asari successively, stir, be concentrated into paste, make the various dosage forms on the pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810159997XA CN101406657B (en) | 2008-11-14 | 2008-11-14 | Chinese medicine compound for treating lung cancer and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810159997XA CN101406657B (en) | 2008-11-14 | 2008-11-14 | Chinese medicine compound for treating lung cancer and manufacturing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101406657A CN101406657A (en) | 2009-04-15 |
| CN101406657B true CN101406657B (en) | 2011-04-13 |
Family
ID=40570002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810159997XA Expired - Fee Related CN101406657B (en) | 2008-11-14 | 2008-11-14 | Chinese medicine compound for treating lung cancer and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101406657B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861089B (en) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Application of Houttuynoid B in medicine for treating liver cancer |
| CN108371694A (en) * | 2018-01-20 | 2018-08-07 | 江西永昇制药股份有限公司 | Compound dandelion cancer curing period Chinese medicine preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408384A (en) * | 2001-09-27 | 2003-04-09 | 张丽 | Pure traditional Chinese medicine preparation for curing lung cancer |
-
2008
- 2008-11-14 CN CN200810159997XA patent/CN101406657B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408384A (en) * | 2001-09-27 | 2003-04-09 | 张丽 | Pure traditional Chinese medicine preparation for curing lung cancer |
Non-Patent Citations (2)
| Title |
|---|
| 王子鑫.中医药治疗肺癌临床研究进展.《第十届全国中西医结合肿瘤学术大会论文汇编》.2006,146-157. * |
| 王忠山.中医药治疗原发性支气管肺癌近况.《中医药研究》.2000,第16卷(第6期),48-51. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101406657A (en) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041312B (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN101757403B (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN102274361A (en) | Anticancer medicinal composition and preparation method of decoction thereof | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN113424956A (en) | Health-care product composition for preventing and treating gynecological lumps and preparation method and application thereof | |
| CN111375010A (en) | A Chinese medicinal composition with effects of strengthening body resistance, consolidating constitution, nourishing liver, invigorating kidney, and enhancing immunity | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN101966321A (en) | Traditional Chinese medicinal composition for treating breast cancer and preparation method thereof | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN102764371B (en) | Traditional Chinese medicine compound prescription for relieving radiotherapy side reactions and preparation method and application thereof | |
| CN102302608B (en) | Chinese medicinal composition for treating anemia and preparation method thereof | |
| CN102078511A (en) | Medicine for promoting leukopoiesis | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN101036741B (en) | Medicine for treating cancer and preparing method therefor | |
| CN107243022A (en) | Traditional Chinese medicine pill for the treatment of cancer and preparation method thereof | |
| CN101406657B (en) | Chinese medicine compound for treating lung cancer and manufacturing method thereof | |
| CN104324331A (en) | Lung tumor suppression cream applied to Qi-stagnation and blood stasis and preparation method of lung tumor suppression cream | |
| CN103142894B (en) | Traditional Chinese medicine composition for rehabilitation of tumor patients after radiotherapy and chemotherapy, and preparation method thereof | |
| CN101647961A (en) | Medicament for gastric cancer and esophagus cancer during postoperation and chemotherapy and preparation method thereof | |
| CN102125645B (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN103223149A (en) | Chinese herb medicine composition for treating lung cancer | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN104147244A (en) | Ginseng and clematis chinensis oral liquid and preparation method thereof | |
| CN111388564B (en) | Traditional Chinese medicine for treating bradyarrhythmia | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUAN LIN Free format text: FORMER OWNER: KOU XUEJUN Effective date: 20101015 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Guan Lin Inventor after: Hu Yuanfeng Inventor after: Yan Jun Inventor after: Guan Hong Inventor before: Kou Xuejun |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KOU XUEJUN TO: GUAN LIN HU YUANFENG YAN JUN GUAN JIANG Free format text: CORRECT: ADDRESS; FROM: 250001 ENERGY-SAVING TECHNOLOGY DEPARTMENT OF JI NAN MUNICIPAL CONSTRUCTIONCOMMITTEE, NO.131, JING ER ROAD, SHIZHONG DISTRICT, JI NAN CITY, SHANDONG PROVINCE TO: 250011 AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (CHINESE MEDICINE HOSPITAL OF SHANDONG PROVINCE), NO.42, WENHUA WEST ROAD, JINAN CITY, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20101015 Address after: 250011 Affiliated Hospital of Shandong University of Traditional Chinese Medicine (Shandong Provincial Traditional Chinese Medical Hospital), 42 West Wenhua Road, Shandong, Ji'nan Province, China Applicant after: Guan Lin Address before: 250001 science and Technology Energy Saving Office of Ji'nan Construction Committee, No. two, No. 131 Road, Ji'nan, Shandong Applicant before: Kou Xuejun |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110413 Termination date: 20111114 |